The FDA approves Mumbai-based Cipla Limited’s generic version of Merck’s (MRK +2.6%)
Proventil HFA (albuterol sulfate) Metered Dose Inhaler, 90
mcg/Inhalation for the treatment or prevention of bronchospasm in
patients at least four years old who have reversible obstructive airway
disease and the prevention of exercise-induced bronchospasm.
This is the first generic Proventil HFA approved in the U.S.
https://seekingalpha.com/news/3559435-fda-oks-generic-version-of-merck-bronchospasm-med
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.